Inovio Pharmaceuticals

Yahoo Finance • last month

Inovio says FDA agrees with rolling BLA submission for rare disease asset

[FDA Headquarters] * The U.S. FDA is in agreement with Inovio Pharmaceuticals (NASDAQ:INO [https://seekingalpha.com/symbol/INO]) regarding its rolling BLA submission plan for INO-3107 for Recurrent Respiratory Papillomatosis. * The ph... Full story

Yahoo Finance • last month

Oppenheimer maintains Outperform rating on Inovio stock amid FDA approval for competitor

Investing.com - Oppenheimer has reiterated an Outperform rating and $13.00 price target on Inovio Pharmaceuticals (NASDAQ:INO) following the FDA approval of a competing therapy for recurrent respiratory papillomatosis (RRP). According to I... Full story

Yahoo Finance • 2 months ago

Gapping stocks in Friday's session

Let's have a look at the gap up and gap down stocks in today's session. [gap] GAP UP STOCKS TICKER CHANGE COMMENT PMNT [https://www.chartmill.com/stock/quote/PMNT/profile] 88.98% PERFECT MOMENT LTD'S (NYSEARCA:PMNT [https... Full story

Yahoo Finance • 2 months ago

Inovio Pharmaceuticals’ SWOT analysis: dna immunotherapy firm’s stock faces pivotal year

Inovio Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company specializing in DNA-based immunotherapies, stands at a critical juncture as it approaches the submission of its Biologics License Application (BLA) for its lead candidate,... Full story

Yahoo Finance • 2 months ago

Inovio rises after promising Q2 results

[Quarterly results] CharlieAJA/iStock via Getty Images Inovio Pharmaceuticals (NASDAQ:INO [https://seekingalpha.com/symbol/INO]) shares up after the company's net loss lowered in Q2 from the previous year period. The company reported a s... Full story

Yahoo Finance • 2 months ago

Hospital Information Systems Company Evaluation Report 2025 | Epic Systems, AdvancedMD, and Dedalus Lead with Integrated EHR, Practice Management, and Digital Transformation Solutions

Dublin, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The "Hospital Information Systems Company Evaluation" report has been added to ResearchAndMarkets.com's offering. The Hospital Information System Companies Quadrant is a comprehensive industr... Full story

Yahoo Finance • 2 months ago

JMP analyst reiterates Market Outperform rating on Inovio stock

Investing.com - JMP Securities has reiterated its Market Outperform rating and $12.00 price target on Inovio Pharmaceuticals (NASDAQ:INO), according to a research note published Wednesday. The target represents significant upside from the... Full story

Yahoo Finance • 2 months ago

INOVIO PHARMACEUTICALS INC (NASDAQ:INO) Reports Q2 2025 Results: Revenue at $0.0, EPS Loss of $0.61 Amid 4.7% After-Hours Drop

INOVIO PHARMACEUTICALS INC (NASDAQ:INO [https://www.chartmill.com/stock/quote/INO/profile]) reported its second-quarter 2025 financial results, posting revenue of $0.0 and an earnings per share (EPS) loss of $0.61. The figures were largely... Full story

Yahoo Finance • 2 months ago

Here are the major earnings after the close Tuesday

Major earnings expected after the bell on Tuesday include: * CoreWeave (CRWV [https://seekingalpha.com/symbol/CRWV]) * Inovio Pharmaceuticals (INO [https://seekingalpha.com/symbol/INO]) * Luminar Technologies (LAZR [https://seekinga... Full story

Yahoo Finance • 2 months ago

Inovalis Real Estate Investment Trust reports Q2 results

* Inovalis Real Estate Investment Trust press release [https://seekingalpha.com/pr/20194529-inovalis-real-estate-investment-trust-announces-the-financial-results-for-q2-2025] (INO.UN:CA): Q2 AFFO -0.02. MORE ON INOVALIS REAL ESTATE INVES... Full story

Yahoo Finance • 3 months ago

Piper Sandler initiates Inovio Pharmaceuticals stock with Overweight rating

Investing.com - Piper Sandler initiated coverage on Inovio Pharmaceuticals (NASDAQ:INO) with an Overweight rating and a $5.00 price target. The stock, currently trading near its 52-week low of $1.30, has declined over 37% in the past week... Full story

Yahoo Finance • 3 months ago

INOVIO announces pricing of $25M public offering

* INOVIO Pharmaceuticals (NASDAQ:INO [https://seekingalpha.com/symbol/INO]) on Thursday priced an underwritten public offering of 14.29 million shares of its common stock, along with accompanying Series A and Series B warrants to purchas... Full story

Yahoo Finance • 3 months ago

Inovio prices $25 million public offering of common stock and warrants

PLYMOUTH MEETING, Pa. - INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) has priced an underwritten public offering of 14,285,715 shares of its common stock along with accompanying warrants at $1.75 per share, according to a press release stateme... Full story

Yahoo Finance • 3 months ago

INOVIO Pharma Announces Proposed Public Offering

(RTTNews) - INOVIO Pharmaceuticals Inc. (INO) announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying Series A warrants a... Full story

Yahoo Finance • 2 years ago

INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights

Achieved significant progress with lead product candidate, INO-3107 Received Breakthrough Therapy designation from U.S. Food and Drug Administration (FDA) as a potential treatment for Recurrent Respiratory Papillomatosis (RRP) Received FD... Full story

Yahoo Finance • 2 years ago

INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Plymouth Meeting, Pa., June 23, 2023 (GLOBE NEWSWIRE) -- INOVIO (NASDAQ:INO) has released the following pursuant to an order of the UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA: UNITED STATES DISTRICT COURT EASTERN D... Full story

Yahoo Finance • 2 years ago

Inovio Pharmaceuticals First Quarter 2023 Earnings: Misses Expectations

Inovio Pharmaceuticals (NASDAQ:INO) First Quarter 2023 Results Key Financial Results Revenue: US$114.9k (down 42% from 1Q 2022). Net loss: US$40.6m (loss narrowed by 49% from 1Q 2022). US$0.16 loss per share (improved from US$0.36 loss i... Full story

Yahoo Finance • 2 years ago

INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023

Safety and Immunological data from both cohorts of the recently completed Phase 1/2 trial will be presented on May 5th PLYMOUTH MEETING, Pa., April 27, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developi... Full story

Yahoo Finance • 2 years ago

European Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO's Application for Orphan Drug Designation for INO-3107

European Commission to review and make a final decision, expected late May 2023 PLYMOUTH MEETING, Pa., April 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to... Full story

Yahoo Finance • 3 years ago

INOVIO to Report Third Quarter 2022 Financial Results on November 8, 2022

PLYMOUTH MEETING, Pa., Oct. 25, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with... Full story